216 related articles for article (PubMed ID: 34674115)
21. Difelikefalin in the Treatment of Chronic Kidney Disease-Associated Pruritus: A Systematic Review.
Wala K; Szepietowski JC
Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 36015082
[TBL] [Abstract][Full Text] [Related]
22. Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: A randomized, double-blind, placebo-controlled trial.
Viscusi ER; Torjman MC; Munera CL; Stauffer JW; Setnik BS; Bagal SN
Clin Transl Sci; 2021 Sep; 14(5):1886-1893. PubMed ID: 33982405
[TBL] [Abstract][Full Text] [Related]
23. Newer and Safer Kappa-Opioid Agonist for Your Patients With Uremic Pruritus.
Lagacé F; Jfri A; Litvinov IV; Netchiporouk E
J Cutan Med Surg; 2020; 24(5):525-526. PubMed ID: 32426990
[No Abstract] [Full Text] [Related]
24. Recent advances in the treatment of uremic pruritus.
Trachtenberg AJ; Collister D; Rigatto C
Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):465-470. PubMed ID: 32740217
[TBL] [Abstract][Full Text] [Related]
25. Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program.
Fishbane S; Wen W; Munera C; Lin R; Bagal S; McCafferty K; Menzaghi F; Goncalves J
Kidney Med; 2022 Aug; 4(8):100513. PubMed ID: 36039153
[TBL] [Abstract][Full Text] [Related]
26. [Diagnosis and management of pruritus associated with chronic kidney disease in hemodialyzed patients].
Lanot A; Misery L; Rostoker G; Testa A; Chauveau P; Touzot M; Florens N; Bataille P
Nephrol Ther; 2024 Feb; 20(1):50-60. PubMed ID: 38294264
[TBL] [Abstract][Full Text] [Related]
27. [Difelikefalin and treatment of severe pruritus associated with chronic kidney disease - Real-life retrospective study in a dialysis center].
Brasme R; Cartery C; Goubet M; Hennino MF; Maisonneuve N
Nephrol Ther; 2024 Jun; 20(3):1-9. PubMed ID: 38874419
[TBL] [Abstract][Full Text] [Related]
28. Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients.
Fishbane S; Mathur V; Germain MJ; Shirazian S; Bhaduri S; Munera C; Spencer RH; Menzaghi F;
Kidney Int Rep; 2020 May; 5(5):600-610. PubMed ID: 32405581
[TBL] [Abstract][Full Text] [Related]
29. Assessment of the physical dependence potential of difelikefalin: Randomized placebo-controlled study in patients receiving hemodialysis.
Spencer RH; Munera C; Shram MJ; Menzaghi F
Clin Transl Sci; 2023 Sep; 16(9):1559-1568. PubMed ID: 37128642
[TBL] [Abstract][Full Text] [Related]
30. Clinically meaningful change in itch intensity scores: An evaluation in patients with chronic kidney disease-associated pruritus.
Vernon M; Ständer S; Munera C; Spencer RH; Menzaghi F
J Am Acad Dermatol; 2021 Apr; 84(4):1132-1134. PubMed ID: 32603719
[No Abstract] [Full Text] [Related]
31. Pruritus in chronic kidney disease.
Uppal NN; Corona A; Fishbane S
Curr Opin Nephrol Hypertens; 2022 Sep; 31(5):435-441. PubMed ID: 35894277
[TBL] [Abstract][Full Text] [Related]
32. Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis.
Guttman-Yassky E; Facheris P; Da Rosa JC; Rothenberg-Lausell C; Del Duca E; David E; Estrada Y; Liu Y; Bose S; Chowdhury M; Munera C; Goncalves J; Nograles K; Kim BS; Lebwohl M
J Allergy Clin Immunol; 2023 Oct; 152(4):916-926. PubMed ID: 37453614
[TBL] [Abstract][Full Text] [Related]
33. Interventions for itch in people with advanced chronic kidney disease.
Hercz D; Jiang SH; Webster AC
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011393. PubMed ID: 33283264
[TBL] [Abstract][Full Text] [Related]
34. Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.
Yagi M; Tanaka A; Namisaki T; Takahashi A; Abe M; Honda A; Matsuzaki Y; Ohira H; Yoshiji H; Takikawa H;
J Gastroenterol; 2018 Oct; 53(10):1151-1158. PubMed ID: 29663077
[TBL] [Abstract][Full Text] [Related]
35. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study.
Kumagai H; Ebata T; Takamori K; Muramatsu T; Nakamoto H; Suzuki H
Nephrol Dial Transplant; 2010 Apr; 25(4):1251-7. PubMed ID: 19926718
[TBL] [Abstract][Full Text] [Related]
36. [Effect of TRK-820, a selective kappa opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis].
Nakao K; Ikeda K; Kurokawa T; Togashi Y; Umeuchi H; Honda T; Okano K; Mochizuki H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Apr; 28(2):75-83. PubMed ID: 18516986
[TBL] [Abstract][Full Text] [Related]
37. Prevalence, patient burden and physicians' perception of pruritus in haemodialysis patients.
Engler F; Kerschbaum J; Keller F; Mayer G;
Nephrol Dial Transplant; 2024 Jan; 39(2):277-285. PubMed ID: 37429597
[TBL] [Abstract][Full Text] [Related]
38. Chronic kidney disease-associated pruritus in patients undergoing hemodialysis: Xerosis and topical therapy.
Krismi A; Danarti R; Setiabudi IIDPP; Wirohadidjojo YW
Hemodial Int; 2023 Apr; 27(2):91-104. PubMed ID: 36811513
[TBL] [Abstract][Full Text] [Related]
39. The association between CKD-associated pruritus and quality of life in patients undergoing hemodialysis in Pakistan: A STROBE complaint cross-sectional study.
Rehman IU; Chan KG; Munib S; Lee LH; Khan TM
Medicine (Baltimore); 2019 Sep; 98(36):e16812. PubMed ID: 31490367
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
